From: Randomized Phase II trial of paclitaxel and carboplatin followed by gemcitabine switch-maintenance therapy versus gemcitabine and carboplatin followed by gemcitabine continuation-maintenance therapy in previously untreated advanced non-small cell lung cancer
arm A
arm B
(n = 25)
(n = 24)
p-value
CR
0
PR
9
4
SD
7
8
PD
5
NE
1
RR(%)
36.0
16.7
0.13
DCR(%)
64.0
50.0
0.32